Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety of combination of Camrelizumab
(Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in
neoadjuvant therapy of Her-2 negative breast cancer patients with HRR gene mutation.